Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results